SecBot SecBot
PRESS-RELEASE ·Filed Jun 2, 2026

LFCR

Lifecore Biomedical, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

The agreement adds to Lifecore's late-stage pipeline but lacks disclosed financial terms, limiting near-term revenue visibility. Monitor future filings for regulatory approval milestones and potential commercial manufacturing scale-up. The stock may see modest positive sentiment from pipeline growth, but no immediate catalyst is present.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$5.45
T+0 close · Jun 2, 2026 · via day close
Latest settled
−14.68%
T+60 · $4.65
Vs SPY
−15.80%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 2 $5.45entry
  2. T+1 · 6mo ago +4.04%α +4.73% · $5.67
  3. T+5 · 5mo ago +3.85%α +6.82% · $5.66
  4. T+20 · 5mo ago −3.30%α −1.74% · $5.27
  5. T+60 · 3mo ago −14.68%α −15.80% · $4.65
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lifecore Biomedical announced a manufacturing services agreement with a leading ophthalmic disease management provider for process development and tech transfer of a next-generation reformulation from vials to pre-filled syringes. This is the sixth late-stage pipeline addition in seven months, but no financial terms or revenue commitments were disclosed.

Key Facts

  • Agreement covers process development and technical transfer services for an injectable ophthalmic product.
  • Program involves transitioning a commercially approved product from vials to pre-filled syringes.
  • This is the sixth late-stage pipeline addition in seven months.
  • No financial terms, deal value, or revenue guidance were disclosed.
  • Commercial manufacturing is contingent upon regulatory approval of the customer's product.

Financial Impact

No financial terms disclosed; revenue potential depends on regulatory approval and future commercial manufacturing volumes.

revenue

Risk Factors

  • Commercial manufacturing revenue is contingent on customer's regulatory approval, which may be delayed or denied.
  • No financial terms disclosed, making it difficult to assess materiality.
  • Customer concentration risk if this program represents a significant portion of future revenue.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
73% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3305014

Track record

20 reports on LFCR

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +45.27% at T+60 after the Mar 26, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $6.42 Now $6.42 +0.08% settles Nov 18
  2. Nov 13, 20263d ago DEFM14A Neutral 6/10 Entry $6.42 Now $6.42 +0.00% settles Nov 17
  3. Nov 5, 202611d ago 8-K / DEFA14A Neutral 5/10 Entry $6.40 to $6.36 Now $6.42 +0.31% ▼ −0.63% −0.94% vs SPY
  4. Nov 4, 202612d ago 8-K Bearish 6/10 No price data
  5. Nov 4, 202612d ago Press Release Bearish 5/10 Entry $6.44 to $6.40 Now $6.42 +0.31% ▲ +0.62% −3.79% vs SPY
  6. Oct 30, 202617d ago PREM14A Neutral 5/10 Entry $6.39 to $6.42 Now $6.42 +0.47% ▲ +0.47% +0.17% vs SPY
  7. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $6.37 to $6.37 Now $6.42 +0.78% · 0.00% +1.18% vs SPY
  8. Sep 28, 20267w ago SC 13D/A Bullish 7/10 Entry $6.59 to $6.58 Now $6.42 −2.58% ▼ −0.15% +0.05% vs SPY
  9. Sep 28, 20267w ago DEFA14A Bullish 7/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
  10. Sep 28, 20267w ago 8-K Bullish 8/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 7h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 2, 2026